Takara Bio Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 1,779

Employees

  • Stock Symbol
  • 4974

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $5.39
  • (As of Friday Closing)

Takara Bio General Information

Description

Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Nojihigashi 7-4-38
  • Kusatsu, Shiga 525-0058
  • Japan
+81
Primary Industry
Biotechnology
Stock Exchange
TKS
Vertical(s)
Corporate Office
  • Nojihigashi 7-4-38
  • Kusatsu, Shiga 525-0058
  • Japan
+81

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Takara Bio Stock Performance

As of 20-Jun-2025, Takara Bio’s stock price is $5.39. Its current market cap is $649M with 120M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.39 $5.35 $4.89 - $7.74 $649M 120M 224K $0.06

Takara Bio Financials Summary

As of 31-Mar-2025, Takara Bio has a trailing 12-month revenue of $295M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023
EV 485,444 485,444 526,547 1,331,820
Revenue 295,365 295,365 301,094 577,197
EBITDA 40,646 40,646 53,367 190,875
Net Income 6,827 6,827 10,243 118,273
Total Assets 837,557 837,557 801,136 969,648
Total Debt 7,358 7,358 6,396 7,295
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Takara Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Takara Bio‘s full profile, request access.

Request a free trial

Takara Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business s
Biotechnology
Kusatsu, Japan
1,779 As of 2025

Basel, Switzerland
 

Minneapolis, MN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Takara Bio Competitors (61)

One of Takara Bio’s 61 competitors is Lonza Group, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lonza Group Corporation Basel, Switzerland
Advanced Cell Diagnostics Formerly VC-backed Minneapolis, MN
J. Craig Venter Institute Corporate Backed or Acquired La Jolla, CA
10x Genomics Formerly VC-backed Pleasanton, CA
BioLegend Formerly Accelerator/Incubator backed San Diego, CA
You’re viewing 5 of 61 competitors. Get the full list »

Takara Bio Patents

Takara Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2024049175-A Method for detecting accurately two bases continuous replacement in variant sars-cov-2 Pending 28-Sep-2022
EP-4502162-A1 Selective regulatory gene (srg) system for genetically modified immune cell therapy Pending 29-Mar-2022
US-20250179147-A1 Selective regulatory gene (srg) system for genetically modified immune cell therapy Pending 29-Mar-2022
EP-4502166-A1 Efficient system for producing adeno-associated virus (aav) vector Pending 25-Mar-2022
US-20250197887-A1 Efficient system for producing adeno-associated virus (aav) vector Pending 25-Mar-2022 C12N15/86
To view Takara Bio’s complete patent history, request access »

Takara Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Takara Bio Investments & Acquisitions (8)

Takara Bio’s most recent deal was a Merger/Acquisition with ViSpot. The deal was made on 27-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ViSpot 27-Jan-2025 Merger/Acquisition Laboratory Services (Healthcare)
StemCells (Stem Cell-related Research Products) 11-Nov-2014 Corporate Asset Purchase Buildings and Property
Cellectis bioresearch (Sweden) 04-Sep-2014 Merger/Acquisition Biotechnology
Nanosphere 26-Apr-2006 Later Stage VC Diagnostic Equipment
Takara Bio USA 01-Aug-2005 Merger/Acquisition Discovery Tools (Healthcare)
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Takara Bio ESG

Risk Overview

Risk Rating

Updated May, 27, 2025

28.01 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Biotechnology

Subindustry

of 366

Rank

Percentile

To view Takara Bio’s complete esg history, request access »

Takara Bio Exits (4)

Takara Bio’s most recent exit was on 26-Apr-2006 from Nanosphere. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Nanosphere 26-Apr-2006 Completed
  • 4 buyers
Helixmith 23-Feb-2005 Completed
  • 10 buyers
Nanosphere 26-Nov-2002 Completed
  • 3 buyers
Helixmith 01-Mar-2000 Corporate Completed
To view Takara Bio’s complete exits history, request access »

Takara Bio FAQs

  • When was Takara Bio founded?

    Takara Bio was founded in 2002.

  • Where is Takara Bio headquartered?

    Takara Bio is headquartered in Kusatsu, Japan.

  • What is the size of Takara Bio?

    Takara Bio has 1,779 total employees.

  • What industry is Takara Bio in?

    Takara Bio’s primary industry is Biotechnology.

  • Is Takara Bio a private or public company?

    Takara Bio is a Public company.

  • What is Takara Bio’s stock symbol?

    The ticker symbol for Takara Bio is 4974.

  • What is the current stock price of Takara Bio?

    As of 20-Jun-2025 the stock price of Takara Bio is $5.39.

  • What is the current market cap of Takara Bio?

    The current market capitalization of Takara Bio is $649M.

  • What is Takara Bio’s current revenue?

    The trailing twelve month revenue for Takara Bio is $295M.

  • Who are Takara Bio’s competitors?

    Lonza Group, Advanced Cell Diagnostics, J. Craig Venter Institute, 10x Genomics, and BioLegend are some of the 61 competitors of Takara Bio.

  • What is Takara Bio’s annual earnings per share (EPS)?

    Takara Bio’s EPS for 12 months was $0.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »